SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Corp, develops and markets drugs for the treatment of the central nervous system. Its product pipeline includes cenobamate, carisbamate, relenopride, SKL24741, SKL20540, SKL27969, SKL13865, and SKL-PSY. SK Biopharmaceuticals provides pipeline products for various indications such as epilepsy, Lennox-Gastaut syndrome, rare neurological diseases, schizophrenia, advanced solid tumors, bipolar disorder, attention deficit hyperactivity disorder, and others. The company has developed drug candidates in the CNS area, including treatments for epilepsy and GI conditions such as chronic constipation and constipation-dominant irritable bowel syndrome. The company reported revenues of USD 273.27 million for the fiscal year ended December 2023 (FY2023), an increase of 44.2% over FY2022.

CNS-focused chemical library Big data and artificial intelligence-based drug design platform Phenotypic Screening Platform

Public

Pharma, CDMO, Bio